Home
HelpTest Code BRGYNSO Invitae Breast and Gyn Cancers Panel (01201)
Additional Codes
Invitae Test Code: 01201
Specimen Requirements
| Fasting Required | Specimen Type | Preferred Container/Tube | Acceptable Container/Tube | Specimen Volume | Specimen Minimum Volume (allows for 1 repeat) |
Pediatric Minimum Volume (no repeat) |
|---|---|---|---|---|---|---|
| No | Whole Blood | EDTA Lavender Top Tube (LTT) | 3 mL | 1.5 mL |
Acceptable Specimen Types
Alternate Specimens: Saliva, assisted saliva, buccal swab and gDNA
Specimen Stability Information
| Specimen Type | Temperature | Time |
|---|---|---|
| Whole Blood | Ambient | 48 hours |
| Refrigerated | 14 days |
Rejection Criteria
| Hemolyzed, clotted, or frozen blood |
|---|
| Blood from patients who have had an allogeneic (non-self donor) bone marrow transplant |
| Blood from patients who have had an allogeneic (non-self donor) stem cell transplant |
| Blood from patients who had a blood transfusion less than two weeks prior to specimen collection |
Test Information
The Invitae Breast and Gyn Cancers Panel analyzes genes that are associated with hereditary predisposition breast, ovarian, and endometrial/uterine cancers. The genetic heterogeneity associated with these conditions can make it difficult to use phenotype as the sole criterion to select a definitive cause. These genes were curated based on the available evidence to date in order to provide analysis for hereditary breast and gynecologic cancers. Given the clinical overlap of hereditary susceptibility to breast and gynecologic cancers, broad panel testing allows for an efficient evaluation of several potential genes based on a single clinical indication. Some genes in this test may also be associated with additional unrelated disorders, which are not included in the list of disorders tested. Genetic testing of these genes may help confirm a clinical diagnosis, help predict disease prognosis and progression, facilitate early detection of symptoms, inform family planning and genetic counseling, or promote enrollment in clinical trials.
Interpretations
An interpretive report will be provided
Reference Range Information
An interpretive report will be provided
Performing Laboratory Name
Invitae
Referral Laboratory Information
| Address | Telephone | Website Link |
|---|---|---|
| 1400 16th Street
San Francisco, CA 94103 |
800-436-3037 |
Performing Information
| Performing Location | Day(s) Test Performed | Analytical Time | Methodology/Instrumentation |
|---|---|---|---|
| Invitae | Monday through Saturday | 10-21 days | Next Generation Sequencing Deletion/Duplication Analysis |
CPT Codes
| CPT | Modifier (if needed) |
Quantity | Description | Comments |
|---|---|---|---|---|
| 81162 | 1 | BRCA1, BRCA2 gene analysis; full sequenceanalysis and full duplication/deletion analysis | If appropriate | |
| 81432 | 1 | Hereditary breast cancer-related disorders;genomic sequence analysis panel, must include sequencing of at least 10 genes,always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, andTP53. | If appropriate | |
| 81433 | 1 | Duplication/deletion analysis panel, must include analysis for BRCA1, BRCA2, MLH1, MSH2, and STK11. | If appropriate |
Outreach CPT Codes
| CPT | Modifier (if needed) |
Quantity | Description | Comments |
|---|---|---|---|---|
| 81162 | 1 | BRCA1, BRCA2 gene analysis; full sequenceanalysis and full duplication/deletion analysis | If appropriate | |
| 81432 | 1 | Hereditary breast cancer-related disorders;genomic sequence analysis panel, must include sequencing of at least 10 genes,always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK11, andTP53. | If appropriate | |
| 81433 | 1 | Duplication/deletion analysis panel, must include analysis for BRCA1, BRCA2, MLH1, MSH2, and STK11. | If appropriate |
Ordering Applications
| Ordering Application | Description |
|---|---|
| COM | Invitae Breast and GYN Cancer Panel (#1201) |
| Cerner | Invitae Breast and GYN Cancer Panel (#1201) |